Iovance Biotherapeutics Inc (NASDAQ:IOVA) achieved the upper end of their 2024 revenue guidance, with total product revenue of $164.1 million. The company has a robust manufacturing network with a ...

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.45 per share a year ago.

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report). The company’s shares closed last Friday at ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on Iovance Biotherapeutics (IOVA – Research Report), with a price target of $6.00. The company’s shares ...

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic ...

The market expects Iovance Biotherapeutics (IOVA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known ...

IOVA Price Action: Iovance shares closed 6.50% lower at $5.32 on Monday, according to Benzinga pro.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SAN CARLOS, Calif. (AP) — SAN CARLOS, Calif. (AP) — Iovance Biotherapeutics Inc. (IOVA) on Thursday reported a loss of $78.6 million in its fourth quarter. On a per-share basis, the San Carlos ...

Rebel forces have been seen in the center of Bukavu, the second largest city in the eastern Democratic Republic of Congo (DRC), on Sunday, residents told CNN, as the fighters push to expand their ...